Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients

Baskent University

Status and phase: Completed; Phase 4

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: rosiglitazone(drug), blood pressure lowering effect

Study type: Interventional

Funder types: Other

Identifiers

NCT00290394

KA03/181

Details and patient eligibility

About

The purpose of this study was to determine the effects of rosiglitazone in normotensive type 2 diabetic patients with regard to its blood-pressure-reducing effects.

Full description

The first study to evaluate the effects of troglitazone on blood pressure in humans was published recently, which demonstrated a 5/4 mm Hg reduction in ambulatory blood pressure in 18 nondiabetic obese subjects after 12 weeks' treatment. Another study in 18 hypertensive subjects with diabetes mellitus showed an 18/12 mm Hg decline in office blood pressure after 8 weeks of treatment.

Sex: All

Ages: 49 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Blood pressure of patients were in normotensive limits according to the JNC VII
• Diabetes mellitus treated with oral antidiabetics or diet

Exclusion criteria

• Any known hypertension, coronary artery disease, congestive hearth failure, renal disease or liver disease
• Anti-hypertensive treatment

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)